INmune Bio, Inc.

INMB Healthcare Biotechnology

INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024. In the quarter to June 2026, revenue grew 8.70%, EPS grew 95.2% and free cash flow grew 55.4%, each against the same quarter a year earlier.

1.57 0.08 −4.85%
Market cap
$45.8M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
4/9
Altman Z
−10.46
Beneish M
−3.67
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
4.17 3.55 4.24 4.04
Net Debt/EBITDA
3.73 4.57 3.71 13.06
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.21) (0.12) (0.13) (0.13)
Book value per Share
0.95 0.95 0.74 0.76
Free Cash Flow
(5.63) (3.09) (3.40) (3.60)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates